The index — which outperformed the Dow Jones, the Nasdaq, and the Biotechnology Index this month — gained more than 8 percent.
Free genetic testing on a broad gene panel is available to children, from birth to five years old, if they've had an unprovoked seizure.
Last week, Invitae launched its Non-Invasive Prenatal Screening test while Myriad expanded its Prequel Prenatal Screen to cover all aneuploidies.
The new channel, to be launched in the second quarter, is part of the company's plan to make genetic testing affordable and accessible to everyone.
For the last three months of 2018, Invitae reported $45.4 million in revenues compared to $25.4 million in Q4 2017, beating the consensus Wall Street estimate.
Invitae and Tulane University researchers found 37 percent of patients with positive germline results were not covered by testing guidelines in place at the time.
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.
In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.
In a preliminary financial report, the company said it is expecting revenues of more than $144 million and to have tested more than 300,000 samples.
The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
The Los Angeles Times reports that only a third of California students meet the state's new science standards.
A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.
In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.